BAVENCIO is a PD-L1 inhibitor that activates dual immune function

PRECLINICAL AND IN VITRO DATA MAY NOT NECESSARILY CORRELATE WITH CLINICAL OUTCOMES.

Graphic Showing BAVENCIO® (avelumab) Mechanism of Action

ADAPTIVE IMMUNE RESPONSE

BAVENCIO has been shown to release the suppression of the T cell-mediated antitumor immune response by blocking the interaction of PD-L1 with PD-1 receptors in preclinical models

INNATE IMMUNE RESPONSE

BAVENCIO has also been shown to induce NK cell-mediated direct tumor cell lysis via antibody-dependent cell-mediated cytotoxicity (ADCC) in vitro

Explore Resources for Your Patients and Practice

Reference: 1. Bavencio Prescribing information. EMD Serono, Inc.; 2024.